Core Viewpoint - Maiwei Bio announced a significant adjustment to its share repurchase plan, increasing the maximum repurchase price from 35.00 yuan to 48.00 yuan per share in response to recent stock price increases and market changes [1] Group 1: Share Repurchase Plan - The company initially planned to repurchase shares at a price not exceeding 35.00 yuan per share for an amount between 25 million to 50 million yuan [1] - As of July 31, the repurchase plan had not been implemented, prompting the board to convene on August 5 to revise the plan [1] - The adjusted repurchase price is expected to allow for the acquisition of approximately 520,000 to 1,040,000 shares, representing 0.13% to 0.26% of the total share capital [1] Group 2: Regulatory Issues - The company's chairman and general manager, Liu Datao, received an administrative penalty from the Shanghai Regulatory Bureau of the China Securities Regulatory Commission for suspected short-term trading [1] - Liu was issued a warning and fined 600,000 yuan as part of the regulatory action [1]

Core Viewpoint - The collaboration between Maiwei Biotech's subsidiary Taikang Biotech and Qilu Pharmaceutical has garnered significant attention, focusing on the licensing agreement for the injectable drug Agrelistat α (brand name: Maili Sheng®) [1] Group 1: Collaboration Details - The licensing agreement grants Maiwei Biotech exclusive rights for Qilu Pharmaceutical to develop, produce, improve, utilize, and commercialize the licensed product in Greater China, including mainland China, Hong Kong, Macau, and Taiwan [1] - Taikang Biotech is set to receive a total of up to 500 million RMB in upfront and milestone payments, along with royalties of up to double-digit percentages of net sales from the licensed product [1] Group 2: Product Information - Agrelistat α is a recombinant human serum albumin-granulocyte colony-stimulating factor (G-CSF) fusion protein, designed to reduce the incidence of infections in adult patients with non-myeloid malignancies undergoing chemotherapy that may cause febrile neutropenia [1] - This product represents a new generation of long-acting G-CSF with independent intellectual property rights, utilizing gene fusion technology to combine high-activity modified G-CSF with human serum albumin (HSA) [2] - The fusion with HSA increases molecular weight and significantly inhibits the clearance pathway mediated by G-CSF receptors, thereby extending the drug's half-life and reducing dosing frequency, which enhances treatment compliance [2] - HSA, being a natural component of human blood, provides a high level of safety as a carrier protein, and the product is produced using a Pichia pastoris expression system, simplifying the manufacturing process compared to chemically modified long-acting products [2]

Core Viewpoint - The chairman and general manager of Maiwei Biotech, Liu Datao, has been penalized for engaging in short-term trading while the company has reported significant losses over the past years [1][2][3]. Group 1: Company Performance - Maiwei Biotech has reported net losses of approximately 10.53 billion yuan and 10.44 billion yuan for 2023 and 2024, respectively, totaling nearly 21 billion yuan in losses over two years [1][6]. - Since its establishment, Maiwei Biotech has never achieved profitability, with cumulative net losses reaching about 54 billion yuan over six years [6][8]. - The company's revenue has shown some growth, with 2023 and 2024 revenues reported at 1.28 billion yuan and 2 billion yuan, reflecting year-on-year increases of 361.03% and 56.28% [6][8]. Group 2: Executive Compensation - Liu Datao received a total compensation of 58.84 million yuan from Maiwei Biotech over a period of less than two years, with 31.78 million yuan in 2023 and 27.04 million yuan in the first ten months of 2024 [1][12][13]. - His compensation includes direct salary and share-based payments, with significant amounts allocated to stock options [12][13]. Group 3: Regulatory Actions - Liu Datao was fined 600,000 yuan and received a warning from the China Securities Regulatory Commission for his short-term trading activities, which involved transactions totaling 33.18 million yuan [1][4][3]. - The regulatory findings were based on evidence including company announcements, inquiry records, and trading data [3][4]. Group 4: IPO Prospects - Maiwei Biotech is in the process of applying for an IPO in Hong Kong, but Liu Datao's legal issues may negatively impact this endeavor [10][11]. - The company has not provided updates on its H-share listing progress for seven months [11].

Core Viewpoint - The company has announced an adjustment to its share repurchase plan, increasing the maximum repurchase price from RMB 35.00 per share to RMB 48.00 per share to ensure the smooth implementation of the plan [7][11][17]. Group 1: Share Repurchase Plan Overview - The company approved a share repurchase plan on June 26, 2025, allowing for the repurchase of its A-shares using self-owned funds and/or special loans, with a total repurchase amount between RMB 25 million and RMB 50 million [1][9]. - The repurchase period is set for 12 months from the date of board approval [1][9]. - As of July 31, 2025, the company has not yet implemented the share repurchase [2][10]. Group 2: Adjustment of Repurchase Price - The maximum repurchase price has been adjusted to RMB 48.00 per share due to the company's stock price exceeding the previous limit, which limited the implementation window [11][15]. - The adjustment is based on the company's confidence in its future development and aims to protect shareholder interests [11][16]. - The total repurchase amount remains unchanged, and the repurchase plan's other details are not affected by this adjustment [16][17]. Group 3: Company’s Business and Market Position - The company focuses on oncology and age-related diseases, with 16 core products in various stages of development, including 12 innovative drugs and 4 biosimilars [12]. - The company has several innovative drugs in critical clinical research stages, with notable achievements such as receiving multiple designations from the FDA for its drug 9MW2821 [12]. - The company has established international partnerships and is expanding its market presence, particularly in emerging markets along the Belt and Road Initiative [13].

Core Viewpoint - The company, Maiwei (Shanghai) Biotechnology Co., Ltd., has announced an adjustment to the upper limit of its share repurchase price from RMB 35.00 per share to RMB 48.00 per share to ensure the smooth implementation of its share repurchase plan [1][2][7] Summary of Share Repurchase Plan - The company plans to repurchase its issued A-shares through centralized bidding on the Shanghai Stock Exchange, with a total repurchase fund not less than RMB 25 million and not exceeding RMB 50 million [1][6] - The repurchase period is set for 12 months from the date of the board's approval of the repurchase plan [1] Reasons for Adjustment - The adjustment to the repurchase price limit is due to the recent continuous rise in the company's stock price, reflecting confidence in the company's future stable development and recognition of its value [2][5] - The new upper limit of RMB 48.00 per share is based on the company's comprehensive consideration of market conditions and the progress of the share repurchase [6][7] Company’s Product Pipeline - The company has a robust pipeline with 16 core products in various stages, including 12 innovative drugs and 4 biosimilars, with 4 already on the market [2][3] - Notable products include 9MW2821, which has received multiple designations from the FDA, and other innovative monoclonal antibodies with significant potential in treating various diseases [3][4] Financial Performance - The company reported a sales revenue of RMB 139 million for its product Deshu Single Antibody in 2024, marking a year-on-year increase of 230.17% [4] - The company has signed licensing agreements with other pharmaceutical companies, which include substantial upfront payments and potential royalties based on sales [5] Decision-Making Process - The adjustment to the repurchase price limit was approved in a board meeting held on August 5, 2025, and does not require shareholder approval [7]

Core Viewpoint - The company, Maiwei (Shanghai) Biotechnology Co., Ltd., has announced a share repurchase plan aimed at utilizing the repurchased shares for employee stock ownership plans or equity incentives, with a total expected repurchase amount between 25 million to 50 million RMB [1][2]. Group 1: Share Repurchase Plan - The share repurchase plan was first disclosed on June 27, 2025, and the implementation period is from June 26, 2025, to June 25, 2026 [1]. - The company plans to repurchase shares using its own funds and/or a special loan for stock repurchase through the Shanghai Stock Exchange trading system [1]. - The maximum repurchase price is not to exceed a specified amount, and the total number of shares repurchased will be reported monthly [2]. Group 2: Progress of Share Repurchase - As of July 31, 2025, the company has not yet implemented the share repurchase plan and will choose the timing based on market conditions [2]. - The company is committed to adhering to relevant regulations during the repurchase period and will disclose progress in a timely manner [2].

8月4日晚间，迈威生物(688062.SH)发布《关于公司董事长兼总经理收到行政处罚决定书的公告》。受 此消息影响，该公司股价今日盘中跌幅一度至3.57%，最终收盘35.52元/股，微跌0.87%，总市值141.9亿 元。随后，该公司发布了回购股份的进展。 证券代码:688062 证券简称:迈威生物 公告编号:2025-039 迈威(上海)生物科技股份有限公司 关于公司董事长兼总经理收到 行政处罚决定书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 上述违法事实,有迈威生物相关公告、相关人员的询问笔录、证券账户资 料、证券交易记录、银行资金明细等证据证明,足以认定。 技术型董事长刘大涛短线交易被罚 资料显示，迈威生物成立于2017年，于2022年1月18日在上交所科创板上市，是一家全产业链布局的创 新型生物制药公司，专注于肿瘤和年龄相关疾病，涉及肿瘤、自身免疫、骨疾病、眼科、血液、感染等 治疗领域。现有16个品种处于不同阶段，包括12个创新品种和4个生物类似药，其中4个品种上市，1个 品种已提交上市许可申请前沟通( ...

证券日报网讯8月5日晚间，迈威生物发布公告称，公司拟将回购价格上限由人民币35.00元/股(含)调整 为人民币48.00元/股(含)。 ...

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 报告显示，2024年A股上市公司所有财务总监平均年薪为81.48万元。而395家生物医药行业上市公司 CFO平均薪酬跃升至91.97万元（中位数约74.23万元），超出全市场均值达12.8%。 聚焦上海地区，39家生物医药（申万一级）企业CFO总薪酬4442.62万元，其平均年薪进一步跃升至 113.91万元（中位数约102.20万元），较市场均值高出39.8%，显著展现区域与行业的双重溢价效应。 迈威生物CFO薪酬排名第三，个人履历显赫 在上海医药生物领域CFO前十强中，迈威生物华俊成为焦点。 根据公开信息，华俊2024年薪酬达277.71万元。需注意的是，2023年度统计的CFO薪酬159.21万元为 2023年6月上任的财务负责人华俊收入，不包括离职的叶茵薪酬。 年报显示，2024年华俊薪酬较2023年报表数据上升118.5万元，增幅74.43%。 新浪财经《2024年度A股CFO数据报告》最新披露，医药生物行业CFO薪酬显著高于A股平均水 ...

Economic News - The Ministry of Commerce reported that China's service trade import and export totaled 38,872.6 billion yuan in the first half of the year, a year-on-year increase of 8.0% [1] - The China Logistics and Purchasing Federation announced that the logistics industry prosperity index for July was 50.5, indicating continued expansion but a slight slowdown in growth [1] - The People's Bank of China and six other departments stated that by 2027, the financial system supporting the high-end, intelligent, and green development of manufacturing will be basically mature [1] - The National Healthcare Security Administration announced that 55 types of drugs will be included in the 11th batch of centralized procurement, with rational bidding from enterprises [1] - The Supreme People's Court reported that 1,156 cases of medical insurance fraud were concluded in 2024, recovering over 400 million yuan in losses [1] - The Shanghai Stock Exchange revealed that the number of new A-share accounts in July increased by 71% year-on-year, reflecting a recovery in the A-share market [1] Company News - China Shipbuilding Industry Corporation plans to absorb and merge China Shipbuilding Heavy Industry Company, leading to the latter's delisting [5] - Green通科技 intends to use 45,040 million yuan of raised funds to acquire a 46.92% stake and invest 8,000 million yuan in Damo Semiconductor, resulting in a 51% stake in the company [5] - Shanghai Washba established a joint venture with Yuyuan Rare Earth New Materials Co., with a registered capital of 200 million yuan [5] - Maiwei Bio's chairman received an administrative penalty from the China Securities Regulatory Commission for suspected short-term trading [5] Bond Market Analysis - The Ministry of Finance announced that starting August 8, 2025, interest income from newly issued government bonds will be subject to VAT, reversing previous exemptions [7] - The policy aims to narrow the tax burden differences in the bond market and is expected to help alleviate fiscal pressure, as public budget revenue decreased by 0.3% year-on-year in the first half of the year [8] - The impact of the VAT restoration on 10-year government bonds is estimated to be around 10 basis points for self-operated accounts and 5 basis points for asset management products [9] - The new tax policy may lead to a widening of the yield spread between new and old bonds, with credit bonds potentially becoming more attractive [10] - The bond market is expected to experience fluctuations in the short term, with a projected yield range of 1.6% to 1.8% [12]